Corxel Pharmaceuticals
13
3
4
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
38%
5 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Role: lead
A Food-Effect Study of CX11 in Healthy Participants
Role: collaborator
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Role: lead
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Role: collaborator
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Role: lead
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Role: lead
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
Role: lead
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
Role: lead
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Role: lead
Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia
Role: lead
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease
Role: lead
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Role: lead
A Study of Etripamil in Healthy Subjects
Role: lead
All 13 trials loaded